What type of gene is FLT3?
The FLT3 gene provides instructions for making a protein called fms-like tyrosine kinase 3 (FLT3), which is part of a family of proteins called receptor tyrosine kinases (RTKs). Receptor tyrosine kinases transmit signals from the cell surface into the cell through a process called signal transduction.
Which of the following is an alias for the gene FLT3?
FLT3 (FMS-like tyrosine kinase 3)
| Alias (NCBI) | CD135 |
|---|---|
| HGNC Alias symb | STK1 |
| FLK2 | |
| CD135 | |
| HGNC Previous name | fms-related tyrosine kinase 3 |
What is FLT3 gene mutation?
FLT3 is a gene change, or mutation, in leukemia cells. Between 20 and 30 percent of people with AML have this mutation. The FLT3 gene codes for a protein called FLT3 that helps white blood cells grow. A mutation in this gene encourages the growth of too many abnormal leukemia cells.
Is FLT3 a proto oncogene?
CD135 is a proto-oncogene, meaning that mutations of this protein can lead to cancer. Mutations of the FLT3 receptor can lead to the development of leukemia, a cancer of bone marrow hematopoietic progenitors.
What is FLT3 ITD AML?
Acute myeloid leukemia with a FLT3 internal tandem duplication (FLT3/ITD) mutation is an aggressive hematologic malignancy with a generally poor prognosis. It can be successfully treated into remission with intensive chemotherapy, but it routinely relapses.
What is FLT3 status?
FMS-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in acute myeloid leukemia and is associated with worse clinical outcome. Changes in FLT3 mutation status can occur during the course of disease, but the clinical impact of a change is unclear.
What are FLT3 inhibitors?
FLT3 inhibitors are tyrosine kinase inhibitors and are classified into first- and second-generation inhibitors based on their kinase specificity and potency. First-generation inhibitors include midostaurin and sorafenib.
What is NPM1 mutation?
Mutations in the NPM1 gene are involved in a form of blood cell cancer known as cytogenetically normal acute myeloid leukemia (CN-AML). While large chromosomal abnormalities can be involved in the development of acute myeloid leukemia, about half of cases do not have these abnormalities; these are classified as CN-AML.
What do FLT3 inhibitors do?
JEL FLT3 inhibitors are tyrosine kinase inhibitors. Like other tyrosine kinase inhibitors, they compete for the adenosine triphosphate (ATP) binding site in the active domain of the kinase, which inhibits the ability of the protein to be phosphorylated, and subsequently decreases in the activity of that protein.
What is the function of the FLT3 gene?
The FLT3 gene provides instructions for making a protein called fms-like tyrosine kinase 3 (FLT3), which is part of a family of proteins called receptor tyrosine kinases (RTKs). Receptor tyrosine kinases transmit signals from the cell surface into the cell through a process called signal transduction.
How is the FLT3 receptor related to tyrosine kinase 3?
FLT3 fms related tyrosine kinase 3 [ (human)] This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. This receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor.
What is the role of FLT3 in AML?
Tocris Summary for FLT3 Gene. FMS-like receptor tyrosine kinase-3 (FLT3) is a member of the class III RTK (receptor tyrosine kinase) family and is expressed primarily in hematopoietic progenitor cells. Its expression in these cells means that FLT3 has an important role in the pathogenesis of AML.
What are the domains of FLT3 and FMS?
A subset of RTKIII family members that includes FLT3, FMS, platelet-derived growth factor receptor (PDGFR), and KIT are characterized by an extracellular domain comprised of 5 immunoglobulinlike (Ig-like) domains and by a cytoplasmic domain with a split tyrosine kinase motif. 5, 6